Hundreds of clinicians, researchers and people with lived experience gathered in Montreal in September 2019 to highlight promising work in hepatitis C research and practice. The 8th International Conference on Hepatitis Care in Substance Users (INHSU 2019) showcased innovative models of care that support the delivery of hepatitis C treatment.
Canada has signed on to the global 90-90-90 targets to end the HIV epidemic by 2030. The aim of these targets is to diagnose at least 90% of all people living with HIV, provide treatment for 90% of those diagnosed, and for 90% of people on treatment to have an undetectable viral load by 2020. However, Canada is falling short on the first 90, lagging behind other similar countries, such as the United Kingdom and Australia.
CATIE recently launched its Can’t Pass It On campaign to increase awareness that people living with HIV on effective treatment can’t pass it on to a partner. The series features real serodifferent couples with one HIV-positive and one HIV-negative partner. CATIE sat down with one of these couples, Rainer Oktovianus and Eka Nasution, to learn more about their story and why they chose to participate in the campaign.
HIV is not what it used to be. Many people with HIV describe it as a chronic condition and a manageable part of their life. HIV prevention is not what it used to be, either. The simultaneous rise of “undetectable equals untransmittable” (U=U) and pre-exposure prophylaxis (PrEP) caused a radical change in the way we talk about HIV transmission and prevention.
Poverty, stigma and criminalization are chronic problems among people who use and inject drugs. But hepatitis C virus (HCV) is no longer such a problem, since it is usually cured by eight to 12 weeks of oral, direct-acting antivirals (DAAs). Delivering DAAs to people who use and inject drugs in the context of the chronic problems facing them is an opportunity to recognize and support the contribution of people with lived experience, and to build and strengthen systems and programs.
Pharmacists are drug therapy experts. We are responsible for ensuring medications are used safely, responsibly and effectively to maximize the benefits of treatment. This is especially true in the provision of care to people living with HIV. But community pharmacists are often seen as separate from the HIV care team. We are largely left out of therapeutic decision-making, despite our central role in dispensing medications. But community pharmacists have demonstrated that we can play a vital role in HIV care.
